NCT01076634View on ClinicalTrials.gov

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.

DRUG

insulin degludec

0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.

Trial Locations (1)

8010

Novo Nordisk Investigational Site, Graz

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY